Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts

Although approximately half of all metastatic colorectal cancers (mCRCs) harbour mutations in KRAS or NRAS, hardly any progress has been made regarding targeted treatment for this group over the last few years. Here, we investigated the efficacy of vertical inhibition of the RAS‐pathway by targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Reissig, Timm M., Ladigan‐Badura, Swetlana, Steinberg, Anja, Maghnouj, Abdelouahid, Li, Ting, Verdoodt, Berlinda, Liffers, Sven T., Pohl, Michael, Wolters, Heiner, Teschendorf, Christian, Viebahn, Richard, Admard, Jakob, Casadei, Nicolas, Tannapfel, Andrea, Schmiegel, Wolff, Hahn, Stephan A., Vangala, Deepak B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620118/
https://www.ncbi.nlm.nih.gov/pubmed/37604687
http://dx.doi.org/10.1002/1878-0261.13510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620118/
https://www.ncbi.nlm.nih.gov/pubmed/37604687
http://dx.doi.org/10.1002/1878-0261.13510

Ejemplares similares